A new drug to treat migraine has been approved by the U.S. Food and Drug Administration.
Reyvow (lasmiditan) tablets were approved for short-term treatment of migraine with or without aura in adults, but not for preventive treatment of migraine.
The approval of the Eli Lilly drug is based on the result of two clinical trials that included a total of nearly 3,200 adults. The most common side effects of Reyvow were dizziness, fatigue, a burning or prickling sensation in the skin and sedation, according to the FDA.
Patients should not drive or operate machinery for at least eight hours after taking Reyvow, the agency added.
Copyright © 2019 HealthDay. All rights reserved.